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Aims
IGF-1 is produced in a GH dependent fashion and mea-
surement of IGF-1 has become increasingly common for
both diagnosis of GH deficiency and to guide GH therapy.
The OZGROW database records the results of IGF-1 tests
performed on patients receiving GH or being assessed for
GH treatment. The OZGROW database was used to
determine the extent to which IGF-1 testing is performed
in this population and to assess the relationship between
IGF-1 levels and growth rate.
Methods
Records were obtained for children entering the
OZGROW database since 2009 and who were currently
receiving GH. Number of patients, visits, and frequency
of IGF-1 tests was determined. The nature of IGF-1
tests, such as the units used and whether a reference
range was provided was noted. Patients with at least one
IGF-1 test result were selected for further analysis. IGF-
1 results were standardized (where a reference range
was available) by expressing them as a % of the refer-
ence range. x% = ((x -L)/(U - L)), where x is the test
result and U and L are the upper and lower values of
the reference range. Growth was measured as either
growth velocity (GV, cm/year) or height SDS/Year over
either a 6month (+/- 10 weeks but adjusted to 6m) or 1
year (+/-13weeks adjusted to 1y). Regressions (coeffi-
cient=b) and correlations (r) were performed.
Results
829 patients were assessed representing 7573 clinic visits.
577 (69%) did not have any IGF-1 tests recorded. 25% had
one test recorded, 4% had two tests, and 1% had three
tests. Another 21 IGF-1 tests were noted but not used in
analyses as no reference range was given. Units used were
nmol/L, mmol/L, U/ml, ug/L, mg/l, and “other”. 11 results
had a reference range but no units. Overall a moderate
but significant relationship was found between IGF-1%
and growth: 6month GV- b=0.014cm/y/%IGF-1, r=0.16,
P=0.01; 6month SDS/y- b=0.005dSDS/y/%IGF-1, r=0.31,
P<0.001. 1Y GV- b=0.010, r=0.14, P=0.03; 1Y SDS/y-
b=0.003, r=0.31, P<0.001. More detailed analyses stratified
by indication and gender will be presented.
Discussion and conclusions
IGF-1 has been recommended to titrate GH dose. We
found significant variation between IGF-1% and growth
response although the correlation was significant. There
was also great variation in measurement units used and
references ranges stated. Further analyses will focus on the
relationship between GH dose and IGF-1% to help fully
elucidate the value of IGF-1 testing in GH treatment.
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